Review of catumaxomab in the treatment of malignant ascites

Malignant ascites is frequently found with various solid tumors, and no established treatment options exist, apart from symptomatic paracentesis. Catumaxomab, a trifunctional bispecific monoclonal antibody, has two binding specificities directed to epithelial cell adhesion molecule (EpCAM) and the T...

Descripción completa

Detalles Bibliográficos
Autor principal: Sebastian, Martin
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004584/
https://www.ncbi.nlm.nih.gov/pubmed/21188120
http://dx.doi.org/10.2147/CMR.S14115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004584/
https://www.ncbi.nlm.nih.gov/pubmed/21188120
http://dx.doi.org/10.2147/CMR.S14115

Ejemplares similares